PDS Biotechnology (PDSB) Q3 2024 earnings summary

Executive summary

• Strong investor and investigator interest in the VERSATILE-003 phase III trial for HPV16-positive head and neck cancer, with trial modifications to reduce cost and time to interim data readout and completion.

• PDS Biotechnology is a clinical-stage immunotherapy company focused on oncology and infectious disease candidates, with no commercial products or revenue to date.

• Encouraging data from the VERSATILE-002 study showed improved median overall survival and objective response rates compared to pembrolizumab alone.

• The company is advancing its pipeline with promising results from the IMMUNOCERV phase II trial in cervical cancer and ongoing development of PDS01ADC for prostate cancer.

• Substantial doubt exists about the company's ability to continue as a going concern for at least 12 months due to recurring losses and the need for additional capital.

Financial highlights

• Net loss for Q3 2024 was $10.7 million ($0.29 per share), compared to $10.8 million ($0.35 per share) in Q3 2023, mainly due to lower operating expenses.

• Cash and cash equivalents totaled $49.8 million as of September 30, 2024.

• Research and development expenses increased to $6.8 million in Q3, up from $6.4 million year-over-year, mainly due to higher manufacturing costs.

• General administrative expenses decreased to $3.4 million from $4.1 million year-over-year, driven by lower personnel and professional fees.

• Operating expenses for Q3 2024 were $10.2 million, down from $10.5 million year-over-year.

Outlook and guidance

• FDA decision on the updated VERSATILE-003 protocol expected by mid-December, with trial initiation planned for Q1 2025.

• Enrollment for VERSATILE-003 expected to take about 18 months, with interim data readout anticipated six months after enrollment completion.

• The company expects continued operating losses and negative cash flows for the foreseeable future and may never become profitable.

• Management plans to fund operations through additional equity or debt financing, collaborations, or government funding, but there is no assurance of success.

• Focus remains on advancing VERSATILE-003, with dose optimization studies for PDS01ADC to resume after trial initiation.